The current stock price of COO is 83.4001 USD. In the past month the price increased by 5.88%. In the past year, price decreased by -7.95%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SOLV | SOLVENTUM CORP | 14.47 | 14.90B | ||
| ALGN | ALIGN TECHNOLOGY INC | 17.83 | 12.37B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 23.22 | 5.12B | ||
| LNTH | LANTHEUS HOLDINGS INC | 11.39 | 4.50B | ||
| HAE | HAEMONETICS CORP/MASS | 17.53 | 3.94B | ||
| ICUI | ICU MEDICAL INC | 19.05 | 3.74B | ||
| XRAY | DENTSPLY SIRONA INC | 8.09 | 2.55B | ||
| NEOG | NEOGEN CORP | 33.07 | 2.08B | ||
| UFPT | UFP TECHNOLOGIES INC | 29.89 | 1.99B | ||
| STAA | STAAR SURGICAL CO | N/A | 1.10B | ||
| EMBC | EMBECTA CORP | 4.34 | 754.78M | ||
| BVS | BIOVENTUS INC - A | 13.54 | 661.25M |
The Cooper Cos, Inc. operates as a medical device company. The company is headquartered in San Ramon, California and currently employs 15,000 full-time employees. The firm operates in two business units: CooperVision and CooperSurgical. CooperVision segment is involved in the contact lens industry. CooperSurgical segment is involved in the fertility and women's health care market through its diversified portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. CooperVision’s products include MyDay daily disposable, MyDay daily disposable toric, MyDay Energys, MyDay multifocal, Biofinity & Biofinity XR, Biofinity Energys. CooperSurgical’s portfolio includes INSORB, Lone Star, and the Doppler Blood Flow Monitor. The company also offers a suite of single-use cordless surgical retractors with an integrated multi-light-emitting diode (LED) light source and dual smoke evacuation channels, and single-use surgical suction devices with an integrated, cordless radial LED light source.
COOPER COS INC/THE
6101 Bollinger Canyon Road, Suite 500
San Ramon CALIFORNIA 94583 US
CEO: Albert G. White III
Employees: 15000
Phone: 19254603600
The Cooper Cos, Inc. operates as a medical device company. The company is headquartered in San Ramon, California and currently employs 15,000 full-time employees. The firm operates in two business units: CooperVision and CooperSurgical. CooperVision segment is involved in the contact lens industry. CooperSurgical segment is involved in the fertility and women's health care market through its diversified portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. CooperVision’s products include MyDay daily disposable, MyDay daily disposable toric, MyDay Energys, MyDay multifocal, Biofinity & Biofinity XR, Biofinity Energys. CooperSurgical’s portfolio includes INSORB, Lone Star, and the Doppler Blood Flow Monitor. The company also offers a suite of single-use cordless surgical retractors with an integrated multi-light-emitting diode (LED) light source and dual smoke evacuation channels, and single-use surgical suction devices with an integrated, cordless radial LED light source.
The current stock price of COO is 83.4001 USD. The price increased by 0.32% in the last trading session.
COOPER COS INC/THE (COO) has a dividend yield of 0.02%. The yearly dividend amount is currently 0.
COO has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
COOPER COS INC/THE (COO) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
COOPER COS INC/THE (COO) has a market capitalization of 16.58B USD. This makes COO a Large Cap stock.
The outstanding short interest for COOPER COS INC/THE (COO) is 3.73% of its float.
ChartMill assigns a technical rating of 8 / 10 to COO. When comparing the yearly performance of all stocks, COO turns out to be only a medium performer in the overall market: it outperformed 54.95% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to COO. COO scores excellent on profitability, but there are some minor concerns on its financial health.
Over the last trailing twelve months COO reported a non-GAAP Earnings per Share(EPS) of 4.13. The EPS increased by 11.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 9.16% | ||
| ROA | 3.02% | ||
| ROE | 4.55% | ||
| Debt/Equity | 0.3 |
24 analysts have analysed COO and the average price target is 91.89 USD. This implies a price increase of 10.18% is expected in the next year compared to the current price of 83.4001.
For the next year, analysts expect an EPS growth of 10.55% and a revenue growth 5.62% for COO